Recurrent Glioblastoma
167
42
64
44
Key Insights
Highlights
Success Rate
70% trial completion
Published Results
34 trials with published results (20%)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 47/100
11.4%
19 terminated out of 167 trials
69.8%
-16.7% vs benchmark
4%
6 trials in Phase 3/4
77%
34 of 44 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 44 completed trials
Clinical Trials (167)
A Multicenter Trial to Identify Optimal Atezolizumab Biomarkers in the Setting of Recurrent Glioblastoma. The MOAB Trial
Sonocloud-9 in Association With Carboplatin Versus Standard-of-Care Chemotherapies (CCNU or TMZ) in Recurrent GBM
Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma
A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM
OLIG2 Inhibitor CT-179 for Recurrent and Newly-diagnosed Glioblastoma
Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma
Spectroscopic MRI, Proton Therapy, and Avastin for Recurrent Glioblastoma
Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma
Alpha Radiation Emitters Device (DaRT) for the Treatment of Recurrent Glioblastoma
DSC-MRI in Measuring rCBV for Early Response to Bevacizumab in Patients With Recurrent Glioblastoma
Pilot Radioembolisation Clinical Trial Assessing Safety and Efficacy in Recurrent Glioma
MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma
Atezolizumab and Cabozantinib for the Treatment of Recurrent Glioblastoma
CARv3-TEAM-E T Cells in Glioblastoma
Hypofractionation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma
BRiTE - Bispecific T Cell Engager for Patients With Glioblastoma
Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent Glioblastoma
Chimeric Antigen Receptor (CAR) T Cells With a Chlorotoxin Tumor-Targeting Domain for the Treatment of MMP2+ Recurrent or Progressive Glioblastoma
Intracranial Genetically Modified Immune Cells (TGFβR2KO/IL13Rα2 CAR T-Cells) for the Treatment of Recurrent or Progressive Glioblastoma or Grade 3 or 4 IDH-Mutant Astrocytoma
Sitagliptin in Recurrent/Progressive Grade 4 Glioma